About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Albiglutide
- Company
- GlaxoSmithKline
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Trial details
-
Completed NCT NCT00354536
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline 60 participants Est. completion 2006-09 5 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00518115
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
Not yet reported GlaxoSmithKline 361 participants Est. completion 2008-05 163 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00537719
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
Not yet reported GlaxoSmithKline 34 participants Est. completion 2008-04-04 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT00838903
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Not yet reported GlaxoSmithKline 1049 participants Est. completion 2013-04 386 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00838916
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
Not yet reported GlaxoSmithKline 779 participants Est. completion 2013-05 337 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00839527
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Not yet reported GlaxoSmithKline 685 participants Est. completion 2013-04 358 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00849017
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
Not yet reported GlaxoSmithKline 309 participants Est. completion 2013-02 262 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00849056
Safety and Efficacy of Albiglutide in Type 2 Diabetes
Not yet reported GlaxoSmithKline 310 participants Est. completion 2013-01 331 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00938158
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
Not yet reported GlaxoSmithKline 75 participants Est. completion 2011-04-12 7 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT00976391
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
Not yet reported GlaxoSmithKline 586 participants Est. completion 2012-05 209 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01077505
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
Not yet reported GlaxoSmithKline 16 participants Est. completion 2010-11-24 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01098461
Dose Ranging Study of Albiglutide in Japanese Subjects
Not yet reported GlaxoSmithKline 215 participants Est. completion 2011-05 30 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01098539
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Not yet reported GlaxoSmithKline 507 participants Est. completion 2012-11 218 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01128894
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Not yet reported GlaxoSmithKline 841 participants Est. completion 2011-09 173 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01147692
A Drug Interaction Study of Simvastatin and Albiglutide
Not yet reported GlaxoSmithKline 40 participants Est. completion 2010-08-27 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01147718
A Drug Interaction Study of Albiglutide and Digoxin
Not yet reported GlaxoSmithKline 30 participants Est. completion 2010-11-29 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01147731
A Drug Interaction Study With Albiglutide and Warfarin
Not yet reported GlaxoSmithKline 16 participants Est. completion 2010-09-09 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01357889
Pharmacokinetics/Pharmacodynamics of Albiglutide
Not yet reported GlaxoSmithKline 283 participants Est. completion 2012-10 30 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01406262
Albiglutide Thorough ECG Study in Healthy Volunteers
Not yet reported GlaxoSmithKline 94 participants Est. completion 2011-12-29Type 2 diabetesView official trial listing → -
Completed NCT NCT01475734
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
Not yet reported GlaxoSmithKline 44 participants Est. completion 2012-07 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01733758
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
Not yet reported GlaxoSmithKline 494 participants Est. completion 2015-02 74 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01777282
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline 374 participants Est. completion 2015-01-27 49 sitesOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT02229227
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline 814 participants Est. completion 2017-07-24 157 sites Stand-aloneType 2 diabetesView official trial listing → -
Withdrawn NCT NCT02229240
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline Est. completion 2015-12 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02284009
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
Not yet reported GlaxoSmithKline 67 participants Est. completion 2017-10-18 32 sites Stand-aloneOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT02465515
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline 9463 participants Est. completion 2018-03-14 607 sites Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT02496221
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
Not yet reported GlaxoSmithKline 20 participants Est. completion 2015-10-13 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02660736
Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects
Not yet reported GlaxoSmithKline 59 participants Est. completion 2016-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02683746
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline 308 participants Est. completion 2017-05-15 70 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT02750930
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Not yet reported GlaxoSmithKline 8 participants Est. completion 2017-03-21 27 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02787551
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Not yet reported Sanofi 514 participants Est. completion 2018-11-17 124 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Terminated NCT NCT02793154
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
Not yet reported GlaxoSmithKline 4 participants Est. completion 2017-03-16 2 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT02802514
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
Not yet reported GlaxoSmithKline 5 participants Est. completion 2017-09-07 1 site Added to GLP-1Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT02846233
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
Not yet reported University of California, San Francisco 22 participants Est. completion 2018-12 1 siteType 2 diabetesView official trial listing → -
Withdrawn NCT NCT03015519
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
Not yet reported GlaxoSmithKline Est. completion 2020-04-20 3 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03492580
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Active, not recruiting NCT NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 siteType 2 diabetes Other conditions: Cardiovascular Events, Renal DiseaseView official trial listing → -
Status unknown NCT NCT06449235
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 siteOther conditions: Type2diabetesView official trial listing → -
Active, not recruiting NCT NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University 23280000 participants Est. completion 2029-06-30 1 siteMetabolic syndromeView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.